Inflammatory factors linked to inhibition of factor VIII gene therapy in hemophilia A

December 8, 2017, Mary Ann Liebert, Inc
Credit: Mary Ann Liebert, Inc., publishers

As a gene therapy cure for hemophilia A moves closer to reality, a new study sheds light on a challenging complication in which a host autoimmune response inhibits the production of normal clotting factor VIII from the transferred FVIII gene. Researchers compared the levels of multiple pro- and anti-inflammatory cytokines in a mouse model of hemophilia A that received FVIII gene therapy at different ages and either did or did not exhibit FVIII inhibitor formation, as presented in an article published in Human Gene Therapy.

The article entitled "A Retrospective Study of Cytokine Profiles Changes in Mice with FVIII Inhibitor Development after Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model" is coauthored by Junjiang Sun, Gene Therapy Center and Eshelman School of Pharmacy, University of North Carolina (UNC, Chapel Hill), and colleagues from UNC, University of Saint Joseph School of Pharmacy (Hartford, CT), Northern Jiangsu People's Hospital (Yangzhou, China), Chinese Academy of Medical Sciences, and Peking Union Medical College (Beijing, China). The researchers reported a shift in the cytokine profiles of mice with FVIII inhibitor development, including significantly increased levels of pro-inflammatory cytokines such as interleukin (IL)-1 and IL-6 and tumor necrosis factor (TNF)-alpha, among others. They also showed a negative correlation between risk factors for FVIII inhibitor development and age at which gene therapy was administered.

"Immune responses represent an important limitation to gene therapy for hemophilia," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "The paper from Dr. Sun's group and their colleagues begins to address factors that may predispose certain individuals to mount a greater immune response against the therapeutic protein produced by the gene therapy vectors and thus benefit less from the ."

Explore further: Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

More information: Junjiang Sun et al, A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus–Mediated Gene Therapy in a Hemophilia A Mouse Model, Human Gene Therapy (2017). DOI: 10.1089/hum.2017.094

Related Stories

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

March 31, 2017
A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward ...

Mini form of replacement gene can delay degeneration in leber congenital amaurosis

October 5, 2017
A new study demonstrates success in using a shortened form of the CEP290 gene for gene therapy in a mouse model of Leber congenital amaurosis type 10 (LCA10), a retinal degenerative disorder that causes childhood blindness. ...

Gene therapy for liver disease advancing with the help of adeno-associated viral vectors

December 30, 2016
Liver-directed gene therapy delivered using adeno-associated viral (AAV) vectors to treat diseases such as hemophilia have advanced into human testing. The potential for continued technological improvements to expand the ...

In crafting new treatments for hemophilia, a 'less is more' approach

October 17, 2016
Hematology researchers have found that blocking the role of a common protein may offer unexpected benefits for patients with the inherited bleeding disorder hemophilia A. The finding offers potential for developing both gene ...

Prednisone may improve effectiveness of AAV-based gene therapy by reducing immune response

June 9, 2017
A new study of gene transfer using adeno-associated virus (AAV)-based gene delivery into skeletal muscle of rhesus macaques showed that oral prednisone reduced immune responses to AAV that can weaken expression of the therapeutic ...

Will AAV vectors have a role in future novel gene therapy approaches?

March 20, 2017
Recombinant adeno-associated virus (rAAV) vectors for delivering therapeutic genes have demonstrated their safety in multiple diseases and clinical settings over the years and are a proven and effective tool that can be used ...

Recommended for you

Researchers find potential new gene therapy for blinding disease

August 20, 2018
The last year has seen milestones in the gene therapy field, with FDA approvals to treat cancer and an inherited blinding disorder. New findings from a team led by University of Pennsylvania vision scientists, who have in ...

New study explains why genetic mutations cause disease in some people but not in others

August 20, 2018
Researchers at the New York Genome Center (NYGC) and Columbia University have uncovered a molecular mechanism behind one of biology's long-standing mysteries: why individuals carrying identical gene mutations for a disease ...

Critical role of DHA on foetal brain development revealed

August 17, 2018
Duke-NUS researchers have found evidence that a natural form of Docosahexaenoic Acid (DHA) made by the liver called Lyso-Phosphatidyl-Choline (LPC-DHA), is critical for normal foetal and infant brain development, and that ...

New algorithm could improve diagnosis of rare diseases

August 17, 2018
Today, diagnosing rare genetic diseases requires a slow process of educated guesswork. Gill Bejerano, Ph.D., associate professor of developmental biology and of computer science at Stanford, is working to speed it up.

Gene silencing critical for normal breast development

August 17, 2018
Researchers have discovered that normal breast development relies on a genetic 'brake', a protein complex that keeps swathes of genes silenced.

Officials remove special rules for gene therapy experiments

August 16, 2018
U.S. health officials are eliminating special regulations for gene therapy experiments, saying that what was once exotic science is quickly becoming an established form of medical care with no extraordinary risks.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.